Daily BriefsMost Read

Most Read: Kokusai Electric , Contemporary Amperex Technology (CATL), Hyundai Motor India , Cameco Corp, Delta Electronics Thailand , Lotes Co, Tsuruha Holdings, Japfa Comfeed Indonesia, MongoDB , Dongbang Medical and more

In today’s briefing:

  • Kokusai Electric (6525 JP): Lock-Up Expiry, Index Deletion, Index Inclusion – It’s All Happening
  • CATL (300750 CH): Index Inclusion Post H-Share Listing
  • Hyundai Motor (HYUNDAI IN): Anchor Lock-Up Expiry Increases Float; Index Inclusions Near
  • Solactive Global Uranium & Nuclear Components Index Rebalance Preview: Potential Changes Next Week
  • Delta Electronics (DELTA TB / 2308 TT): Off the Peak; SET50 Deletion Risk Increases
  • Taiwan: Potential Global Index Changes; Last Review Day Today
  • Tsuruha (3391) – Welcia (3141) Future Merger Ratio – Pounding the Table
  • IDX30/​​LQ45/IDX80 Index Rebalance: Big Impact in Some Stocks with 4 Days to Implementation
  • Nasdaq100 Dec2025 Forecast (Part 1): MDB & BIIB in Trouble; UAL & ALNY First Replacements
  • Dongbang Medical IPO Book Building Results Analysis


Kokusai Electric (6525 JP): Lock-Up Expiry, Index Deletion, Index Inclusion – It’s All Happening

By Brian Freitas


CATL (300750 CH): Index Inclusion Post H-Share Listing

By Brian Freitas


Hyundai Motor (HYUNDAI IN): Anchor Lock-Up Expiry Increases Float; Index Inclusions Near

By Brian Freitas

  • The lock-up on the second half of the anchor investor allocation for Hyundai Motor India (HYUNDAI IN) ends after market close today and the shares will be available for sale tomorrow.
  • The lock-up expiry further increases free float for the stock and there will be multiple index inclusions over the next few months.
  • The largest index inclusion will be in February, followed by smaller inclusions in March and June. In total, passives will mop up around 16% of the float.

Solactive Global Uranium & Nuclear Components Index Rebalance Preview: Potential Changes Next Week

By Brian Freitas

  • Based on prices and turnover from 22 January, there could be one deletion from the index in January. Plus there will be capping and float changes.
  • There are four stocks that meet the inclusion criteria, but all are non-pure play companies, and the index is already at the limit of 15 non-pure play companies.
  • Estimated one-way turnover is 6.8% resulting in a round-trip trade of US$506m. There are many stocks with multiple days of ADV to trade.

Delta Electronics (DELTA TB / 2308 TT): Off the Peak; SET50 Deletion Risk Increases

By Brian Freitas


Taiwan: Potential Global Index Changes; Last Review Day Today

By Brian Freitas

  • There could be 2 adds and 2 deletes for Taiwan in a global index in February. Today is the last trading day ahead of the CNY holidays.
  • Passive trackers will need to trade between US$76m to US$370m of the stocks and impact will vary between 3.2x-7x ADV to trade.
  • Shorts are small in the potential adds and there has been short covering recently, while there has been a big increase in shorts for one of the potential deletes.

Tsuruha (3391) – Welcia (3141) Future Merger Ratio – Pounding the Table

By Travis Lundy

  • In late December, a Jiji article said Tsuruha & Welcia would look to integrate by end-2025, now that they no longer need SEC approval. Odd language, but we’ll take it.
  • That means we look to what might happen between here and there. The companies will hire Legal and Financial Advisors, wait until both report FY, then start negotiating.
  • What has been the long-term trend and the trend of the last two years is different. It’s worthwhile looking at valuations and expectations to decide how to trade. It’s good.

IDX30/​​LQ45/IDX80 Index Rebalance: Big Impact in Some Stocks with 4 Days to Implementation

By Brian Freitas


Nasdaq100 Dec2025 Forecast (Part 1): MDB & BIIB in Trouble; UAL & ALNY First Replacements

By Dimitris Ioannidis


Dongbang Medical IPO Book Building Results Analysis

By Douglas Kim

  • Dongbang Medical reported excellent IPO book building results. The IPO price has been finalized at 10,500 won. The demand ratio from the institutional investors was 910 to 1.
  • Our base case valuation of Dongbang Medical is target price of 13,609 won per share which is 30% higher than the IPO price of 10,500 won.
  • Dongbang Medical specializes in the manufacturing and distribution of acupuncture needles, various cosmetic devices, and other medical devices.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars